Stanford, CA, United States of America

Lingyin Li

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2023

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations in Cancer Treatment by Inventor Lingyin Li

Introduction

Lingyin Li is a prominent inventor based in Stanford, California. He has made significant contributions to the field of cancer treatment through his innovative research and patented inventions. With a total of two patents, his work focuses on the development of ENPP1 inhibitors and their applications in oncology.

Latest Patents

Lingyin Li's latest patents revolve around ENPP1 inhibitors and their use for the treatment of cancer. These patents provide compounds, compositions, and methods aimed at inhibiting ENPP1. The methods include contacting a sample with an ENPP1 inhibitor to inhibit the cGAMP hydrolysis activity of ENPP1. In certain instances, the ENPP1 inhibitor is designed to be cell impermeable. The patents also detail methods for treating cancer, which involve administering a therapeutically effective amount of an ENPP1 inhibitor to a subject. This treatment is particularly relevant for solid tumor cancers. Additionally, the patents describe methods of administering radiation therapy either before or after the ENPP1 inhibitor, with the goal of reducing radiation damage to the subject. The methods can be performed in combination with chemotherapeutic agents or checkpoint inhibitors.

Career Highlights

Lingyin Li is affiliated with Leland Stanford Junior University, where he conducts his research and development work. His innovative approach to cancer treatment has positioned him as a key figure in the field. His contributions are not only significant in terms of patents but also in advancing the understanding of cancer therapies.

Collaborations

Lingyin Li collaborates with notable colleagues, including Mark Smith and Kelsey Erin Shaw. These partnerships enhance the research efforts and contribute to the development of effective cancer treatments.

Conclusion

Lingyin Li's work in developing ENPP1 inhibitors represents a significant advancement in cancer treatment. His innovative patents and collaborations highlight the importance of research in finding effective therapies for cancer patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…